These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

184 related articles for article (PubMed ID: 39241774)

  • 1. Detecting altered hepatic lipid oxidation by MRI in an animal model of MASLD.
    McLeod M; Chang MC; Rushin A; Ragavan M; Mahar R; Sharma G; Badar A; Giacalone A; Glanz ME; Malut VR; Graham D; Sunny NE; Bankson JA; Cusi K; Merritt ME
    Cell Rep Med; 2024 Sep; 5(9):101714. PubMed ID: 39241774
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Suppression of hepatic ChREBP⍺-CYP2C50 axis-driven fatty acid oxidation sensitizes mice to diet-induced MASLD/MASH.
    Zhang D; Zhao Y; Zhang G; Lank D; Cooke S; Wang S; Nuotio-Antar A; Tong X; Yin L
    Mol Metab; 2024 Jul; 85():101957. PubMed ID: 38740087
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Improvement of MASLD and MASH by suppression of hepatic N-acetyltransferase 10.
    Yang Y; Lu J; Liu Y; Zhang N; Luo Y; Ma M; Dong Z; Zhang S; Zheng MH; Ruan CC; Wan X; Hu C; Lu Y; Ma X; Zhou B
    Mol Metab; 2024 Nov; 89():102030. PubMed ID: 39293565
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Polyoxometalates Ameliorate Metabolic Dysfunction-Associated Steatotic Liver Disease by Activating the AMPK Signaling Pathway.
    Wang D; Wang J; Yin Z; Gong K; Zhang S; Zha Z; Duan Y
    Int J Nanomedicine; 2024; 19():10839-10856. PubMed ID: 39479173
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Choline-deficient, high-fat diet-induced MASH in Göttingen Minipigs: characterization and effects of a chow reversal period.
    Hvid H; Hjuler ST; Bedossa P; Tiniakos DG; Kamzolas I; Harder LM; Xue Y; Perfield JW; Kirk RK; Latta M; Mikkelsen LF; Pedersen HD;
    Am J Physiol Gastrointest Liver Physiol; 2024 Oct; 327(4):G571-G585. PubMed ID: 39041677
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Nuclear miR-204-3p mitigates metabolic dysfunction-associated steatotic liver disease in mice.
    Zou Z; Liu X; Yu J; Ban T; Zhang Z; Wang P; Huang R; Zheng F; Chang Y; Peng W; Tang Y; Feng X; Zhao Z; Lv X; Huang S; Guo J; Tuo Y; Zhou Z; Liang S
    J Hepatol; 2024 Jun; 80(6):834-845. PubMed ID: 38331323
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Protective Effects of Hepatocyte Stress Defenders, Nrf1 and Nrf2, against MASLD Progression.
    Akl MG; Li L; Widenmaier SB
    Int J Mol Sci; 2024 Jul; 25(15):. PubMed ID: 39125617
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Probiotic Mixture Ameliorates a Diet-Induced MASLD/MASH Murine Model through the Regulation of Hepatic Lipid Metabolism and the Gut Microbiome.
    Zhang F; Lo EKK; Chen J; Wang K; Felicianna ; Ismaiah MJ; Leung HKM; Zhao D; Lee JC; El-Nezami H
    J Agric Food Chem; 2024 Apr; 72(15):8536-8549. PubMed ID: 38575146
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Molecular pathogenesis of metabolic dysfunction-associated steatotic liver disease, steatohepatitis, hepatic fibrosis and liver cirrhosis.
    Saito T; Tsuchishima M; Tsutsumi M; George J
    J Cell Mol Med; 2024 Jun; 28(12):e18491. PubMed ID: 38894579
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Therapeutic siRNA targeting PLIN2 ameliorates steatosis, inflammation, and fibrosis in steatotic liver disease models.
    Wang Y; Zhou J; Yang Q; Li X; Qiu Y; Zhang Y; Liu M; Zhu AJ
    J Lipid Res; 2024 Oct; 65(10):100635. PubMed ID: 39187042
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Suppression of STK39 weakens the MASLD/MASH process by protecting the intestinal barrier.
    Xu Q; Liu F; Wu Z; Chen M; Zhou Y; Shi Y
    Biosci Trends; 2024 Jul; 18(3):289-302. PubMed ID: 38925962
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Repurposing of the analgesic Neurotropin for MASLD/MASH treatment.
    Tsuchiya T; Kim SY; Matsuda M; Kim J; Stotland A; Naiki M; Seki E
    Hepatol Commun; 2024 Aug; 8(8):. PubMed ID: 39023282
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Sex-based differences in natural killer T cell-mediated protection against diet-induced steatohepatitis in Balb/c mice.
    Cuño-Gómiz C; de Gregorio E; Tutusaus A; Rider P; Andrés-Sánchez N; Colell A; Morales A; Marí M
    Biol Sex Differ; 2023 Nov; 14(1):85. PubMed ID: 37964320
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Genetic Ablation of STE20-Type Kinase MST4 Does Not Alleviate Diet-Induced MASLD Susceptibility in Mice.
    Caputo M; Andersson E; Xia Y; Hou W; Cansby E; Erikson M; Lind DE; Hallberg B; Amrutkar M; Mahlapuu M
    Int J Mol Sci; 2024 Feb; 25(4):. PubMed ID: 38397122
    [TBL] [Abstract][Full Text] [Related]  

  • 15. miR-33 deletion in hepatocytes attenuates MASLD-MASH-HCC progression.
    Fernández-Tussy P; Cardelo MP; Zhang H; Sun J; Price NL; Boutagy NE; Goedeke L; Cadena-Sandoval M; Xirouchaki CE; Brown W; Yang X; Pastor-Rojo O; Haeusler RA; Bennett AM; Tiganis T; Suárez Y; Fernández-Hernando C
    JCI Insight; 2024 Aug; 9(19):. PubMed ID: 39190492
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Ablation of IFNγ in myeloid cells suppresses liver inflammation and fibrogenesis in mice with hepatic small heterodimer partner (SHP) deletion.
    Zhu L; Litts B; Wang Y; Rein JA; Atzrodt CL; Chinnarasu S; An J; Thorson AS; Xu Y; Stafford JM
    Mol Metab; 2024 May; 83():101932. PubMed ID: 38589002
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Increased hepatic putrescine levels as a new potential factor related to the progression of metabolic dysfunction-associated steatotic liver disease.
    Núñez-Sánchez MÁ; Martínez-Sánchez MA; Sierra-Cruz M; Lambertos A; Rico-Chazarra S; Oliva-Bolarín A; Balaguer-Román A; Yuste JE; Martínez CM; Mika A; Frutos MD; Llamoza-Torres CJ; Córdoba-Chacón J; Ramos-Molina B
    J Pathol; 2024 Sep; 264(1):101-111. PubMed ID: 39022853
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Fibroblast growth factor 21 is a hepatokine involved in MASLD progression.
    Gallego-Durán R; Ampuero J; Maya-Miles D; Pastor-Ramírez H; Montero-Vallejo R; Rivera-Esteban J; Álvarez-Amor L; Pareja MJ; Rico MC; Millán R; Robles-Frías MJ; Aller R; Rojas Á; Muñoz-Hernández R; Gil-Gómez A; Gato S; García-Lozano M; Arias-Loste MT; Abad J; Calleja JL; Andrade RJ; Crespo J; González-Rodríguez Á; García-Monzón C; Andreola F; Pericás JM; Jalan R; Martín-Bermudo F; Romero-Gómez M
    United European Gastroenterol J; 2024 Oct; 12(8):1056-1068. PubMed ID: 38894596
    [TBL] [Abstract][Full Text] [Related]  

  • 19. RASSF4 Attenuates Metabolic Dysfunction-Associated Steatotic Liver Disease Progression via Hippo Signaling and Suppresses Hepatocarcinogenesis.
    Xu C; Fang T; Qu J; Miao Y; Tian L; Zhang M; Zhuang H; Sun B; Chen L
    Cell Mol Gastroenterol Hepatol; 2024; 18(2):101348. PubMed ID: 38697356
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Drug-Induced Fatty Liver Disease (DIFLD): A Comprehensive Analysis of Clinical, Biochemical, and Histopathological Data for Mechanisms Identification and Consistency with Current Adverse Outcome Pathways.
    López-Pascual E; Rienda I; Perez-Rojas J; Rapisarda A; Garcia-Llorens G; Jover R; Castell JV
    Int J Mol Sci; 2024 May; 25(10):. PubMed ID: 38791241
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.